Robert Lufkin: Anti-Amyloid Drugs Fail Alzheimer’s Patients
Robert Lufkin, Advisor of Metabolic Health and Longevity Expert, shared post on LinkedIn:
“A Cochrane review of 17 trials and 20,342 patients concluded anti-amyloid drugs offer no clinically meaningful benefit for Alzheimer’s.
As a medical school professor, I have watched the amyloid hypothesis dominate Alzheimer’s research for 30 years.
Findings:
- 17 trials, 20,342 patients
- Effects on cognitive decline absent or trivial
- The drugs remove amyloid but raise brain bleeding and swelling risk
- Authors call for research on other mechanisms
Lead author Dr. Francesco Nonino:
‘These drugs make no meaningful difference to patients.’
This is the textbook story I called out in ‘Lies I Taught in Medical School.’
The amyloid hypothesis was elegant.
As a target, it was wrong.
Growing evidence points to Alzheimer’s as a metabolic disease – driven by insulin resistance, glucose hypometabolism, and mitochondrial dysfunction.
Metabolic dysfunction is the root cause of chronic disease.
Full breakdown coming on the Health Longevity Secrets podcast.
View Cochrane review.”
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 30, 2026, 16:52Tosin Ola: A New Era in Sickle Cell Disease Treatment and the Question of Access
-
Oct 30, 2026, 16:48Cedric Hermans: The Next Generation of FVIIIa-Mimetic Antibodies in Haemophilia A
-
Oct 30, 2026, 16:44Shehab Mohamed: Recognizing Isolated Thrombocytopenia as a Presentation of MDS
-
Oct 30, 2026, 16:40Amrita Sarkar: Advancing the Diagnosis of Anti-PF4 Syndromes
-
Oct 30, 2026, 16:35James Garrard: Driving Innovation in Stroke Care Through Global Collaboration
-
Oct 30, 2026, 16:19Cesar de Almeida Neto: Hemo 2026 Roundtable Focuses on the Challenges of Patient Blood Management
-
Oct 30, 2026, 16:01Marilena Vrana: The Case for Retaining Immunoglobulins on the EU Critical Medicines List
-
Oct 30, 2026, 15:53Ilenia Calcaterra: Patient Blood Management Across Complex Hematological Conditions
-
Oct 30, 2026, 15:40Isabella Presch: The Practicalities of Gene Therapy Adoption in Hemophilia